Log in to your Inderes Free account to see all free content on this page.
OncoZenge
4.15
SEK
+3.75 %
ONCOZ
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
+3.75%
-59.79%
-31.86%
+18.4%
+34.3%
+18.57%
-60.1%
-
-66.09%
oncozenge.se/investerare
OncoZenge is a Swedish pharmaceutical company that develops treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. After completing phase 2 studies, the company's product candidate is under further development as a basis for applying for regulatory market approvals and commercialization. OncoZenge is headquartered in Bromma.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
ONCOZ
Daily low / high price
3.85 / 4.16
SEK
Market cap
48.61M SEK
Turnover
184.59K SEK
Volume
46K
Financial calendar
Annual report
20.02.2025
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Niclas Holmgren | 11.8 % | 11.8 % |
| Linc AB | 10.0 % | 10.0 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Redeye: OncoZenge Q3 2024 - Approaching lift-off
Redeye: Redeye Initiates Coverage of OncoZenge
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio